更新于：2024-11-04
Betamethasone Sodium Phosphate
磷酸钠倍他米松
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C22H30FNa2O8P |
InChIKeyODEOTKLZVXBMJD-LWCNAHDDSA-N |
CAS号151-73-5 |
关联
17
项与 磷酸钠倍他米松 相关的临床试验Efficacy of Intramuscular Glucocorticoid Injection in Patients With Lumbar Radicular Pain
Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy (PRE-EASE)
Timing of Late Preterm Corticosteroid Administration and Neonatal Hypoglycemia
100 项与 磷酸钠倍他米松 相关的临床结果
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的转化医学
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的专利（医药）
登录后查看更多信息
425
项与 磷酸钠倍他米松 相关的文献（医药）2024-10-01JOURNAL OF CONTROLLED RELEASE
Reprogramming monocytes into M2 macrophages as living drug depots to enhance treatment of myocardial ischemia-reperfusion injury
Article
作者: Zhang, Zongquan ; Liu, Yan ; Xu, Maochang ; Jiang, Jun ; Li, Chunhong ; Deng, Yiping ; Zhou, Xiangyu ; Zhang, Yingying ; Zhou, Meiling ; Wang, Xueqin
Delivering therapeutic agents efficiently to inflamed regions remains an intractable challenge following myocardial ischemia-reperfusion injury (MI/RI) due to the transient nature of the enhanced permeability and retention effect, which disappears after 24 h. Leveraging the inflammation-homing and plasticity properties of circulating monocytes (MN) as hitchhiking carriers and further inducing their polarization into anti-inflammatory phenotype macrophages upon reaching the inflamed sites is beneficial for MI/RI therapy. Herein, DSS/PB@BSP nanoparticles capable of clearing reactive oxygen species and inhibiting inflammation were developed by employing hollow Prussian blue nanoparticles (PB) as carriers to encapsulate betamethasone sodium phosphate (BSP) and further modified with dextran sulfate sodium (DSS), a targeting ligand for the scavenger receptor on MN. This formulation was internalized into MN as living cell drug depots, reprogramming them into anti-inflammation type macrophages to inhibit inflammation. In vitro assessments revealed the successful construction of the nanoparticle. In a murine MI/RI model, circulating MN laden with these nanoparticles significantly enhanced drug delivery and accumulation at the cardiac injury site, exhibiting favorable therapeutic ability and promoting M2-biased differentiation. Our study provides an effective approach with minimally invasion and biosecurity that makes this nanoplatform as a promising candidate for immunotherapy and clinical translation in the treatment of MI/RI.
2024-10-01FOOD AND CHEMICAL TOXICOLOGY
Cytotoxic effects induced by combined exposure to the mycotoxins sterigmatocystin, ochratoxin A and patulin on human tumour and healthy 3D spheroids
Article
作者: Quagliata, Martina ; Zingales, Veronica ; Cimetta, Elisa ; Esposito, Maria Rosaria ; Ruiz, María-José
Humans are exposed to complex mixtures of mycotoxins through diet. Despite the serious threat they pose, mycotoxin risk assessment often overlooks co-exposure. With the aim of filling this gap, the present study investigates the combined cytotoxicity of sterigmatocystin (STE), ochratoxin A (OTA) and patulin (PAT) in human tumour Neuroblastoma and healthy Mesenchymal Stem Cells three-dimensional (3D) spheroids. The range of concentrations tested (1.56-50 μM for STE, 0.78-25 μM for OTA and 0.15-5 μM for PAT) was selected considering the IC50 values obtained in previous studies and the estimated dietary exposure of consumers. To ensure appropriate experimental conditions, assessments for single mycotoxins and their combinations were conducted simultaneously. The nature of the toxicological interactions among the mycotoxins was then defined using the isobologram analysis. Our results demonstrated increased cytotoxicity in mycotoxin mixtures compared to individual exposure, with abundance of synergistic interactions. These findings highlight that the co-occurrence of STE, OTA and PAT in food may increase their individual toxic effects and should not be underestimated. Moreover, the use of advanced culture models increased the reliability and physiological relevance of our results which can serve as a groundwork for formulating standardized regulatory approaches towards mycotoxin mixtures in food and feed.
2024-09-01Cureus Journal of Medical Science
Comparative Study of the Safety and Efficacy of Intramuscular Dexamethasone, Betamethasone Phosphate, and Standard Management Protocol in Early-Term Scheduled Caesarean Delivery.
Article
作者: Kori, Shreedevi ; Yaliwal, Rajasri G ; Gupta, Namita ; Mudanur, Subhashchandra
Background Babies born between 37 weeks +0 days and 38 weeks +6 days by scheduled caesarean delivery before the onset of labour are more prone to developing respiratory complications than babies delivered between 39 weeks +0 days and 40 weeks +0 days. Antenatal corticosteroids have been used in preterm births for lung maturity. The advantages of administering antenatal corticosteroids before a scheduled caesarean delivery in the early term remain a subject of debate. While some studies have reported benefits, including a reduction in respiratory issues, the evidence is still inconclusive. The study's main objective is to compare the efficacy and safety of intramuscular dexamethasone and betamethasone phosphate with standard treatment protocols in early-term infants. Methodology A total of 241 pregnant women scheduled for caesarean delivery were screened for eligibility to participate in the study. Out of these, 192 women met the inclusion criteria and were enrolled in the study after providing written informed consent; they were randomised into three groups, with 64 in each group, and were given either betamethasone phosphate or dexamethasone intramuscularly or were considered under standard management protocol (no administration of corticosteroids). The primary comparison was done to observe the development of respiratory distress syndrome, transient tachypnoea in newborns, and the need for neonatal intensive care unit (NICU) admission. Results Among 192 pregnant females observed, the incidence of development of respiratory distress syndrome did not differ significantly between the betamethasone, dexamethasone, and standard management groups, with rates of 6.25%, 7.81%, and 4.7%, respectively. Additionally, out of the 192 infants, 15 required neonatal intensive care, including 6 (9.4%) from the betamethasone group, 5 (7.8%) from the dexamethasone group, and 4 (6.3%) from the standard management group. All of these infants had a maximum stay of four days in the NICU, did not require mechanical support, and improved with oxygen therapy. Conclusion In our study, in early-term gestation, both the corticosteroid groups showed similar effects to those of the standard management group in reducing neonatal morbidity, with no significant statistical difference. Hence, the choice lies with the treating obstetrician to consider the administration of corticosteroids in early-term caesarean deliveries.
100 项与 磷酸钠倍他米松 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 溃疡性结肠炎 | 日本 | 1992-03-13 | |
| 克罗恩病 | 日本 | 1992-03-13 | |
| 睑缘炎 | 日本 | 1985-11-20 | |
| 结膜炎 | 日本 | 1985-11-20 | |
| 角膜炎 | 日本 | 1985-11-20 | |
| 耳炎 | 日本 | 1985-11-20 | |
| 炎症 | 美国 | 1974-12-31 | |
| 胶原蛋白疾病 | 日本 | 1973-01-31 | |
| 内分泌系统疾病 | 日本 | 1973-01-31 | |
| 心脏衰竭 | 日本 | 1973-01-31 | |
| 肾病综合征 | 日本 | 1973-01-31 | |
| 类风湿关节炎 | 日本 | 1973-01-31 | |
| 眼部炎症 | 日本 | 1964-10-07 | |
| 外耳炎 | 日本 | 1964-10-07 | |
| 中耳炎 | 日本 | 1964-10-07 | |
| 过敏性鼻炎 | 日本 | 1964-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | (Bupivacaine Hydrochloride and Betamethasone Sodium Phosphate) | 憲範遞鹹簾積鹹範糧鹽(積鹽艱遞積顧鹹壓襯衊) = 醖衊範齋膚淵齋衊壓齋 鹹淵艱衊鏇鑰壓襯鏇簾 (繭鹹淵築醖鹽艱壓衊膚, 構衊膚憲鹹鏇選顧鹽壓 ~ 餘範獵蓋餘網願壓鏇簾) 更多 | - | 2020-11-02 | ||
(Bupivacaine Hydrochloride) | 憲範遞鹹簾積鹹範糧鹽(積鹽艱遞積顧鹹壓襯衊) = 鏇夢網顧憲窪觸餘遞鏇 鹹淵艱衊鏇鑰壓襯鏇簾 (繭鹹淵築醖鹽艱壓衊膚, 蓋淵衊壓膚壓願鬱築襯 ~ 淵憲積遞衊糧醖醖簾觸) 更多 | ||||||
N/A | 糖尿病 blood glucose levels | 5 | 築醖淵廠餘簾壓製遞襯(艱醖鹹構襯獵顧鬱製鑰) = 構製遞膚窪鏇醖構壓觸 築獵範艱窪簾齋夢齋鹽 (壓廠積齋襯築願鬱膚淵 ) | 积极 | 2009-06-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用